Brief: Philogen Withdraws Its EMA Marketing Authorization Application For Nidlegy
25/06/2025 09:35
June 25 (Reuters) - Philogen SpA PHIL.MI: WITHDRAWS THE APPLICATION FOR MARKETING AUTHORIZATION TO EUROPEAN MEDICINES AGENCY FOR NIDLEGY DECISION TO WITHDRAW WAS DUE TO TIMING OF AVAILABILITY OF CHEMISTRY MANUFACTURING AND CONTROLS, ADDITIONAL CLINICAL DATA TO BETTER CHARACTERIZE BENEFIT:RISK PROFILE Further company coverage: PHIL.MI (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48587696600;))
Recent news on Philogen
See all newsBrief: Philogen H1 Net Loss €19.6 Mln
Brief: Philogen Resubmits To EMA Marketing Authorization Application For Nidlegy
Brief: Sun Pharma Says Partner Philogen's Phase II Flash Study In Soft Tissue Sarcoma Did Not Meet Primary Endpoint
Brief: Philogen Reports FY EBITDA Of EUR 261.6 Million
Brief: Philogen H1 Net Loss EUR 14,894